Stockscreener 앱 받기
76.33
1.14%
-0.88
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Spinal Muscular Atrophy Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Insider Trends: Does Ionis Pharmaceuticals Inc have consistent dividend growthJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Revenue Check: Can Ionis Pharmaceuticals Inc scale operations efficiently2025 Institutional Moves & Low Risk High Reward Ideas - baoquankhu1.vn
JPM26: Tryngolza set to become first wholly owned Ionis blockbuster - Yahoo Finance
CEO Change: Can Ionis Pharmaceuticals Inc outperform in the next rally2025 Pullback Review & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return - Yahoo Finance
Trend Recap: Why retail investors favor Ionis Pharmaceuticals Inc. stockJuly 2025 Setups & Long-Term Capital Growth Strategies - Bộ Nội Vụ
How reliable is Ionis Pharmaceuticals Inc. (ISI) stock dividend growthSector Rotation Strategies & Free Unmatched Market Performance - bollywoodhelpline.com
Lobbying Update: $60,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts - The Joplin Globe
Precision Trading with Ionis Pharmaceuticals Inc. (IONS) Risk Zones - Stock Traders Daily
Ionis Pharmaceuticals (IONS) Stock Analysis: Biotech Innovator with 12.69% Upside Potential - DirectorsTalk Interviews
Will Ionis Pharmaceuticals Inc. stock outperform international peersBull Run & Weekly Watchlist for Hot Stocks - Улправда
Ionis Pharmaceuticals EVP Devers sells $3.7m in shares By Investing.com - Investing.com Nigeria
Insider Sell Alert: Shannon Devers Sells 44,199 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 44,199 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Ionis chalks up rare disease win with zilganersen - The Pharma Letter
How resilient is Ionis Pharmaceuticals Inc. stock in market downturns2025 Price Action Summary & Weekly Stock Breakout Alerts - Улправда
Will Ionis Pharmaceuticals Inc. (ISI) stock benefit from infrastructure billEarnings Recap Report & Accurate Buy Signal Alerts - Улправда
Momentum Shift: Will Ionis Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - Улправда
Will Ionis Pharmaceuticals Inc. stock recover faster than peersEntry Point & Daily Risk Controlled Trade Plans - ulpravda.ru
Book value per share of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView — Track All Markets
How Ionis Pharmaceuticals Inc. stock compares to industry benchmarksGap Down & Technical Pattern Based Buy Signals - ulpravda.ru
Can Ionis Pharmaceuticals Inc. stock sustain market leadershipTrade Entry Summary & Community Consensus Picks - Улправда
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies - Nasdaq
Sentiment Review: Why Ionis Pharmaceuticals Inc. stock could see breakout soon - Улправда
Why Ionis Pharmaceuticals Inc. stock is a value investor pickTrade Exit Report & Risk Adjusted Buy/Sell Alerts - Улправда
Ionis Pharmaceuticals stock hits 52-week high at 83.62 USD By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals (IONS) Is Up 5.1% After Hepatitis B Drug Hits Phase 3 GoalsHas The Bull Case Changed? - Sahm
Why Ionis Pharmaceuticals (IONS) Is Up 5.1% After Hepatitis B Drug Hits Phase 3 Goals And What's Next - Yahoo Finance
GSK’s hep B approach hits functional cure goal in pivotal trials - BioWorld MedTech
GSK Gets Closer to Bringing Patients a Functional Cure for Chronic Hepatitis B - MedCity News
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Benzinga
GSK, Ionis claim study success for RNA-based hepatitis B drug - BioPharma Dive
Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 52-Week HighHere's Why - MarketBeat
Ionis Pharmaceuticals stock hits 52-week high at 83.62 USD - Investing.com
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Hepatitis B Market to Witness Promising Upswing by 2034, - openPR.com
GSK Scores An R&D Win With Bepirovirsen Phase III Hep B Data - Citeline News & Insights
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B - BioSpace
Ionis Pharmaceuticals Announces Positive Phase 3 Results for Bepirovirsen - TradingView — Track All Markets
GSK’s hepatitis B drug shows positive results in phase 3 trials - Investing.com Canada
Ionis Pharmaceuticals Inc Stock Analysis and ForecastEarnings Volatility Patterns & Budget Friendly Capital Growth - earlytimes.in
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Bitget
Ionis Pharmaceuticals EVP Research Sells Shares - TradingView — Track All Markets
Treatment-resistant Hypertension Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Idorsia Pharma, Ionis Pharma, KBP Biosciences, KBP Biosciences, Quantum Genomics - Barchart.com
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference - MEXC
Ionis to present at 44th Annual JP Morgan Healthcare Conference - FinancialContent
Nucleic Acid Therapeutics Market to Reach US$ 14.42 Billion - openPR.com
Assessing Ionis Pharmaceuticals (IONS) Valuation After Analyst Optimism And FDA Approval Of Tryngolza - Sahm
Wells Fargo Raises Price Target for Ionis Pharmaceuticals (IONS) to $100 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring A 10.44% Upside Potential - DirectorsTalk Interviews
Ionis Pharmaceuticals (LTS:0JDI) EV-to-FCF : -39.27 (As of Jan. 05, 2026) - GuruFocus
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN
Stock Traders Buy High Volume of Ionis Pharmaceuticals Call Options (NASDAQ:IONS) - MarketBeat
Diversified Trust Co Invests $1.02 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Death Cross: Can Ionis Pharmaceuticals Inc stock continue upward trendMarket Movers & Reliable Breakout Forecasts - moha.gov.vn
Revenues Not Telling The Story For Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - 富途牛牛
Ionis Pharmaceuticals Sees Rapid Rise On RNA Drug Progress - Finimize
162,800 Shares in Ionis Pharmaceuticals, Inc. $IONS Bought by Capricorn Fund Managers Ltd - MarketBeat
4.73%
0.92%
자본화:
|
볼륨(24시간):